|
| Discuss Divis Laboratories Ltd is expected to show a 105 percent leap in net profit.... at the Equities within the Traderji.com - Discussion forum for Stocks Commodities & Forex; Mid-cap drug cos seen posting strong quarterly profit Tue Oct 16, 2007 9:20am ... |
|
|||||||
| Register | Blogs | FAQ | Chat Room | Search | Today's Posts | Mark Forums Read |
| Equities Discuss & analyse stock market news, views, trends and your favourite stocks here. |
|
Welcome to the Traderji.com - Discussion forum for Stocks Commodities & Forex. You are currently viewing our boards as a guest which gives you limited access to view most discussions and access our other features. By joining our free community you will have access to post topics, communicate privately with other members (PM), respond to polls, upload content and access many other special features. Registration is fast, simple and absolutely free so please, join our community today! If you have any problems with the registration process or your account login, please read the FAQ. |
 |
|
|
Thread Tools |
| Sponsored Links |
|
#1
16th October 2007, 05:38 PM
|
|||
|
|||
Divis Laboratories Ltd is expected to show a 105 percent leap in net profit....
Mid-cap drug cos seen posting strong quarterly profit
Tue Oct 16, 2007 9:20am IST MUMBAI (Reuters) - Mid-cap drug companies are seen reporting a substantial rise in net profit for the September quarter backed by acquisitions and presence in geographically diverse markets, analysts said. The rupee's 12.5 percent rise against the dollar so far this year, including a 2 percent gain in July-September alone, will not hurt a majority of these firms as their exports is not all concentrated to the United States. "They are not so highly dependent on U.S. as the large cap companies. They are well diversified in several semi-regulated markets," Sarabjit Kour Nangra, vice president-research for pharmaceuticals at Angel Broking said. A Reuters poll forecast a 29 percent net profit growth for Jubilant Organosys as it consolidates its Hollister-Stier acquisition, and driven by a robust growth in its contract research and manufacturing business (CRAMS). However, net profit growth for bigger CRAMS rival, Nicholas Piramal India Ltd, is seen at 8.3 percent, hurt by higher costs at its Morpeth, UK unit and the rising rupee. Wockhardt Ltd too is expected to turn in a paltry 7.2 percent rise in net profit due to higher costs, despite a 111 percent leap in revenue after integrating its Pinewood, Dumex and Negma acquisitions. "Indian Pharma companies, which have already adopted inorganic growth opportunities, will continue to remain actively involved in the global consolidation wave," Religare institutional equity research said in a note. Divis Laboratories Ltd is expected to show a 105 percent leap in net profit, the highest amongst the mid-cap firms polled by Reuters, to 641 million rupees, aided by tax benefits from its new special economic zone. A low base in the year-ago quarter is seen helping Glenmark Pharmaceuticals Ltd post a 95 percent surge in quarterly net profit. Net profit for the Indian arm of multinational companies -- Aventis Pharma Ltd and Pfizer Ltd -- are expected to record a fall of 2.2 percent and 1.2 percent respectively. --------------------------------------------------------------- RON.  
|
|
| Thread Tools | |
|
|
Indemnity, Disclaimer & Disclosure
Notice:
• By visiting Traderji.com you indicate your acceptance of our Forum
Rules Disclaimer & Disclosure and indemnify Traderji.com, its
associates and related parties of all claims howsoever resulting from
the usage of the forum.
• Disclaimer: Trading or investing in stocks & commodities
is a high risk activity. Any action you choose to take in the markets
is totally your own responsibility. Traderji.com will not be liable for
any, direct or indirect, consequential or incidental damages or loss
arising out of the use of this information.
• Disclosure: The information in this forum is neither an offer
to sell nor solicitation to buy any of the securities mentioned herein.
The writers may or may not be trading in the securities mentioned.
• All names or products mentioned are trademarks or registered trademarks of their respective owners.
General Content Disclaimer Notice:
In light of our policy of encouraging candid, open exchanges of views and the rapid distribution of information originating from many sources, Traderji.com cannot determine the accuracy of information that may be uploaded to the forum. Opinions, advice and all other information expressed by participants in discussions are those of the author. You rely on such information at your own risk. You are urged to seek professional advice for specific, individual situations and not rely solely on advice or opinions given in the discussions. Since Traderji.com is an open and free discussion forum, any comments made by members of this forum in their posts reflect their own views and not of the owner or administrator of Traderji.com. Thus the owner/administrator indemnify themselves of all claims whatsoever and will not be liable or responsible for any members comments/views in this forum Traderji.com. If you find any objectionable or offensive posts made by members of this forum which you would like to bring to our notice for removal then please Contact Us.
Re: Divis Laboratories Ltd is expected to show a 105 percent leap in net profit....
